다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

TSVT

2seventy bio (TSVT)

2seventy bio Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:TSVT

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/17	07:40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:TSVT	2seventy bio Inc
2024/05/10	05:03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:TSVT	2seventy bio Inc
2024/05/08	20:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TSVT	2seventy bio Inc
2024/05/08	20:00	Business Wire	2seventy bio Reports First Quarter Financial Results and Recent Operational Progress	NASDAQ:TSVT	2seventy bio Inc
2024/05/03	20:00	Business Wire	2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024	NASDAQ:TSVT	2seventy bio Inc
2024/04/05	22:05	Business Wire	U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy	NASDAQ:TSVT	2seventy bio Inc
2024/04/01	20:30	Business Wire	2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron	NASDAQ:TSVT	2seventy bio Inc
2024/03/21	06:04	Business Wire	2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors	NASDAQ:TSVT	2seventy bio Inc
2024/03/16	07:27	Business Wire	FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy	NASDAQ:TSVT	2seventy bio Inc
2024/03/08	06:02	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:TSVT	2seventy bio Inc
2024/03/05	21:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TSVT	2seventy bio Inc
2024/03/05	21:00	Business Wire	2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress	NASDAQ:TSVT	2seventy bio Inc
2024/03/01	21:00	Business Wire	2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences	NASDAQ:TSVT	2seventy bio Inc
2024/02/06	06:05	Business Wire	2seventy bio to Participate in Upcoming Investor Conferences	NASDAQ:TSVT	2seventy bio Inc
2024/02/05	21:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TSVT	2seventy bio Inc
2024/02/05	20:59	Business Wire	Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study	NASDAQ:TSVT	2seventy bio Inc
2024/02/03	06:54	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:TSVT	2seventy bio Inc
2024/01/30	23:25	AllPennyStocks.com	Biotech Shares Soar Premarket On Sale Of R&D Assets	NASDAQ:TSVT	2seventy bio Inc
2024/01/30	21:48	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TSVT	2seventy bio Inc
2024/01/30	21:01	Business Wire	2seventy bio Announces New Strategic Path Forward	NASDAQ:TSVT	2seventy bio Inc
2024/01/06	06:31	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:TSVT	2seventy bio Inc
2023/12/12	21:25	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:TSVT	2seventy bio Inc
2023/12/12	09:30	Business Wire	Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3	NASDAQ:TSVT	2seventy bio Inc
2023/12/11	21:00	Business Wire	2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)	NASDAQ:TSVT	2seventy bio Inc
2023/12/07	04:00	Business Wire	2seventy bio Reiterates Commitment to Maximizing Shareholder Value	NASDAQ:TSVT	2seventy bio Inc
2023/12/01	20:49	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:TSVT	2seventy bio Inc
2023/12/01	20:46	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:TSVT	2seventy bio Inc
2023/12/01	20:43	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:TSVT	2seventy bio Inc
2023/12/01	20:40	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:TSVT	2seventy bio Inc
2023/11/21	04:31	Dow Jones News	Trending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA	NASDAQ:TSVT	2seventy bio Inc

검색 관련기사 보기:NASDAQ:TSVT

1 2 3 4 5 6 7 다음 >>

BNP Paribas Issuance

CI Alternative North Ame...

Societe Generale Effekten

BNP Paribas Issuance

Societe Generale Effekten

Bnp Paribas Issuance

Esm Tf 0% Mz25 Eur

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관